top of page

© Copyright 2012 Chemical Biology Ventures Limited. All Rights Reserved. Registered in England & Wales number 7968150. Registered office: 30 Upper High Street, Thame, Oxfordshire, OX9 3EZ. Address for correspondence: 123 Alexander Close, Abingdon, Oxfordshire, OX14 1XD

Production of HIV-based virus-like particles

Virus engineering

Contact CBV

oCCl-2VPK6Xpo0quDAQvpIrSJzI

Tel: +44 (0) 1235 532481

Mob:          07836 554231

Email: email@chembioventures.com

Complex problems often require elegant solutions. Virus-like particles have potential as non-infectious vaccines & as delivery vehicles for heterologous antigens & therapeutic proteins. The toxicity of HIV glycoprotein expression in mammalian cells limited production of recombinant particles. Re-engineering the HIV genome enabled efficient production of budded VLPs.

Structure of a minimal HIV construct expressing Gag, Tat & Rev proteins & containing regulatory elements tar & rre

Example:

Production of HIV-based Virus-like particles

 

Problem:

The HIV glycoprotein is "toxic" & cannot be overexpressed in mammalian cells

 

Solution:

Re-engineer the HIV genome to express Gag within a natural Tat/tar, Rev/rre regulatory & RNA splicing context. Electron micrographs of transfected Vero cells demonstrated expression of budding virus-like particles

 

Patent Link:

Czaplewski LG PROTEINACEOUS PARTICLES CONTAINING RETROVIRAL ELEMENT

HIV
CBVlogo4
bottom of page